Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at ...

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.